Treatment Resistant Depression Global Clinical Trials Review, H2, 2018
- GDHC5245CTIDB
- Pages: 224
- August 2018
- Total Views:1130
- Region : Global
- GlobalData
- Market Research Report
Details
Treatment Resistant Depression Global Clinical Trials Review, H2, 2018
Summary
GlobalData's clinical trial report, Treatment Resistant Depression Global Clinical Trials Review, H2, 2018" provides an overview of Treatment Resistant Depression clinical trials scenario. This report provides top line data relating to the clinical trials on Treatment Resistant Depression. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 25
In Progress Trials by Phase 26
Clinical Trials by Trial Status 27
Clinical Trials by End Point Status 29
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Treatment Resistant Depression Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Treatment Resistant Depression 37
Jun 26, 2018: Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138, a Novel, Oral Small Molecule for Treatment-Resistant Depression 37
Jun 19, 2018: Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe 37
Clinical Trial Profile Snapshots 40
Appendix 222
Abbreviations 222
Definitions 222
Research Methodology 223
Secondary Research 223
About GlobalData 223
Contact Us 224
Disclaimer 224
Source 224
List Of Figure
List of Figures
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Treatment Resistant Depression Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Treatment Resistant Depression Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Treatment Resistant Depression Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Treatment Resistant Depression Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Treatment Resistant Depression Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
Treatment Resistant Depression Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 15
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 16
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 21
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Phase (%), 2018* 25
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 26
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Trial Status, 2018* 27
Treatment Resistant Depression Therapeutics Clinical Trials, Global, by End Point Status, 2018* 29
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 30
Treatment Resistant Depression Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 31
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 32
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 34
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36
GlobalData Methodology 223
List Of Table
List of Tables
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Region, 2018* 7
Treatment Resistant Depression Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Treatment Resistant Depression Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Treatment Resistant Depression Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Treatment Resistant Depression Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Treatment Resistant Depression Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
Treatment Resistant Depression Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 15
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 17
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 22
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Phase, 2018* 25
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 26
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Treatment Resistant Depression Therapeutics Clinical Trials, Global, by End Point Status, 2018* 29
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 30
Treatment Resistant Depression Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 31
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Treatment Resistant Depression Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Treatment Resistant Depression, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Johnson & Johnson
F. Hoffmann-La Roche Ltd
AstraZeneca Plc
Bristol-Myers Squibb Co
Eli Lilly and Co
Otsuka Holdings Co Ltd
Alkermes Plc
The Lundbeck Foundation
Relmada Therapeutics Inc
Evotec AG
Company Profile
Company Profile Title
Treatment Resistant Depression Global Clinical Trials Review, H2, 2018
Summary
GlobalData's clinical trial report, Treatment Resistant Depression Global Clinical Trials Review, H2, 2018" provides an overview of Treatment Resistant Depression clinical trials scenario. This report provides top line data relating to the clinical trials on Treatment Resistant Depression. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 25
In Progress Trials by Phase 26
Clinical Trials by Trial Status 27
Clinical Trials by End Point Status 29
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Treatment Resistant Depression Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Treatment Resistant Depression 37
Jun 26, 2018: Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138, a Novel, Oral Small Molecule for Treatment-Resistant Depression 37
Jun 19, 2018: Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe 37
Clinical Trial Profile Snapshots 40
Appendix 222
Abbreviations 222
Definitions 222
Research Methodology 223
Secondary Research 223
About GlobalData 223
Contact Us 224
Disclaimer 224
Source 224
List Of Figure
List of Figures
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Treatment Resistant Depression Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Treatment Resistant Depression Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Treatment Resistant Depression Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Treatment Resistant Depression Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Treatment Resistant Depression Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
Treatment Resistant Depression Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 15
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 16
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 21
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Phase (%), 2018* 25
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 26
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Trial Status, 2018* 27
Treatment Resistant Depression Therapeutics Clinical Trials, Global, by End Point Status, 2018* 29
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 30
Treatment Resistant Depression Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 31
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 32
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 34
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36
GlobalData Methodology 223
List Of Table
List of Tables
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Region, 2018* 7
Treatment Resistant Depression Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Treatment Resistant Depression Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Treatment Resistant Depression Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Treatment Resistant Depression Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Treatment Resistant Depression Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
Treatment Resistant Depression Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 15
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 17
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 22
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Phase, 2018* 25
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 26
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Treatment Resistant Depression Therapeutics Clinical Trials, Global, by End Point Status, 2018* 29
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 30
Treatment Resistant Depression Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 31
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Treatment Resistant Depression Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Treatment Resistant Depression, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Johnson & Johnson
F. Hoffmann-La Roche Ltd
AstraZeneca Plc
Bristol-Myers Squibb Co
Eli Lilly and Co
Otsuka Holdings Co Ltd
Alkermes Plc
The Lundbeck Foundation
Relmada Therapeutics Inc
Evotec AG
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020